Skip header and navigation

1 records – page 1 of 1.

Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients.

https://arctichealth.org/en/permalink/ahliterature289343
Source
Eur J Clin Nutr. 2016 07; 70(7):824-30
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
07-2016
Author
I A Eide
D O Dahle
M Svensson
A Hartmann
A Åsberg
K S Bjerve
J H Christensen
E B Schmidt
M E Lauritsen
K Lund
T Jenssen
Author Affiliation
Section of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
Source
Eur J Clin Nutr. 2016 07; 70(7):824-30
Date
07-2016
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Adult
Blood Glucose - metabolism
Blood Pressure - drug effects
Cardiovascular Diseases - blood - etiology - prevention & control
Cholesterol, HDL - blood
Cohort Studies
Cross-Sectional Studies
Diet
Dietary Fats - blood - pharmacology
Fatty Acids, Omega-3 - blood - pharmacology
Female
Fish Oils - blood
Heart Rate - drug effects
Humans
Kidney - surgery
Kidney Transplantation - adverse effects
Male
Middle Aged
Norway
Phospholipids - metabolism
Pulse Wave Analysis
Risk factors
Seafood
Triglycerides - blood
Abstract
Cardiovascular (CV) disease is the leading cause of death after renal transplantation. Marine n-3 polyunsaturated fatty acids (PUFAs) exert potential cardio-protective metabolic effects and might reduce CV morbidity and mortality in renal transplant recipients (RTRs).
In this cross-sectional study of 1990 Norwegian RTRs, transplanted between 1999 and 2011, associations between plasma phospholipid marine n-3 PUFA levels and various CV risk markers at 10 weeks after transplant were evaluated.
Higher plasma marine n-3 PUFA levels were associated with lower resting heart rate (rHR), lower fasting plasma glucose (fPG) levels, lower plasma triglyceride levels and higher plasma high-density lipoprotein (HDL) cholesterol levels. Plasma levels of eicosapentaenoic acid, but not docosahexaenoic acid, showed a positive association with plasma HDL cholesterol levels. Plasma marine n-3 PUFA levels were not associated with plasma low-density lipoprotein cholesterol levels, pulse wave velocity or systolic and diastolic blood pressure. A negative association between plasma marine n-3 PUFA levels and CV mortality was weakened by additional adjustment for plasma triglyceride levels and rHR. The ratio of n-6 to n-3 PUFAs showed similar associations with CV risk markers as absolute plasma marine n-3 PUFA levels.
This is the first study in RTRs showing that marine n-3 PUFAs are negatively associated with rHR and fPG in addition to beneficial effects on plasma HDL cholesterol and triglyceride levels. Especially, effects on autonomic nervous function and triglyceride metabolism might contribute to explain the lower CV mortality risk with higher plasma marine n-3 PUFA levels previously shown in this cohort.
Notes
Cites: N Engl J Med. 2011 Jun 23;364(25):2439-50 PMID 21696310
Cites: Am J Clin Nutr. 1992 Jun;55(6):1126-34 PMID 1350705
Cites: Nephron. 1998 Sep;80(1):57-60 PMID 9730704
Cites: Am J Kidney Dis. 1987 Jan;9(1):60-5 PMID 3544824
Cites: Am J Clin Nutr. 2009 Sep;90(3):613-20 PMID 19625683
Cites: BMJ. 1996 Mar 16;312(7032):677-8 PMID 8597736
Cites: Br J Nutr. 2013 Mar 28;109(6):1123-34 PMID 22846205
Cites: BMC Public Health. 2014 Feb 20;14:186 PMID 24555673
Cites: Clin J Am Soc Nephrol. 2013 Nov;8(11):1968-78 PMID 23929933
Cites: Transplantation. 2007 Apr 15;83(7):831-8 PMID 17460552
Cites: Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9 PMID 9820470
Cites: J Clin Lipidol. 2012 Jan-Feb;6(1):5-18 PMID 22264569
Cites: J Am Soc Nephrol. 2005 Aug;16(8):2462-70 PMID 15958723
Cites: Am J Cardiol. 2006 Nov 15;98(10):1393-5 PMID 17134636
Cites: Atherosclerosis. 2006 Nov;189(1):19-30 PMID 16530201
Cites: J Hypertens. 2002 Aug;20(8):1493-9 PMID 12172309
Cites: Am J Clin Nutr. 2011 Oct;94(4):973-80 PMID 21865334
Cites: Pediatr Transplant. 2012 Dec;16(8):835-9 PMID 22835217
Cites: Am J Transplant. 2010 Feb;10(2):338-53 PMID 20415903
Cites: Diabetes Care. 1992 Mar;15(3):430-41 PMID 1559410
Cites: Br J Nutr. 2012 Jun;107 Suppl 2:S214-27 PMID 22591895
Cites: Am J Clin Nutr. 2011 Aug;94(2):543-51 PMID 21677058
Cites: Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1246-56 PMID 26063768
Cites: Heart. 2014 Apr;100(7):569-73 PMID 24352736
Cites: Am J Clin Nutr. 2011 Sep;94(3):884-91 PMID 21775559
Cites: Am J Clin Nutr. 2012 Jun;95(6):1445-53 PMID 22572642
Cites: J Ren Nutr. 2012 Nov;22(6):525-32 PMID 22698988
Cites: Ann Intern Med. 2011 Aug 2;155(3):160-70 PMID 21810709
Cites: Arch Intern Med. 2012 May 14;172(9):686-94 PMID 22493407
Cites: Am J Clin Nutr. 2011 Feb;93(2):446-54 PMID 21147858
Cites: Atherosclerosis. 2008 Mar;197(1):12-24 PMID 18160071
Cites: Lancet. 1999 Aug 7;354(9177):447-55 PMID 10465168
Cites: Circulation. 2006 Jan 17;113(2):195-202 PMID 16401768
Cites: Kidney Int. 2013 Jun;83(6):1130-5 PMID 23389417
Cites: Lancet. 2011 Oct 15;378(9800):1419-27 PMID 22000138
Cites: N Engl J Med. 2012 Jul 26;367(4):309-18 PMID 22686415
Cites: Am J Clin Nutr. 2015 Jul;102(1):49-57 PMID 26016867
Cites: Am J Clin Nutr. 2006 Jun;83(6 Suppl):1505S-1519S PMID 16841861
Cites: Blood Coagul Fibrinolysis. 1995 Feb;6(1):17-22 PMID 7795149
Cites: Transplantation. 2015 Aug;99(8):1730-7 PMID 25757216
Cites: Lancet. 2007 Mar 31;369(9567):1090-8 PMID 17398308
Cites: Evid Rep Technol Assess (Summ). 2005 Feb;(115):1-11 PMID 15810864
Cites: N Engl J Med. 1990 Mar 22;322(12):795-801 PMID 2137901
Cites: Metabolism. 1997 Dec;46(12 Suppl 1):40-3 PMID 9439558
Cites: Nutr Metab Cardiovasc Dis. 2014 Dec;24(12):1310-6 PMID 25063539
Cites: Nutr Metab Cardiovasc Dis. 2007 Oct;17 (8):572-80 PMID 17127043
Cites: Diabetes Care. 2014;37(1):189-96 PMID 24026545
Cites: Ann Intern Med. 2006 Aug 15;145(4):247-54 PMID 16908915
Cites: Eur J Clin Nutr. 2015 Mar;69(3):322-8 PMID 25248358
Cites: Nephrol Dial Transplant. 2014 Jan;29(1):128-36 PMID 23229929
PubMed ID
26931669 View in PubMed
Less detail